Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. (2022)
Attributed to:
Respiratory infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(21)00751-9
PubMed Identifier: 34953520
Publication URI: http://europepmc.org/abstract/MED/34953520
Type: Journal Article/Review
Volume: 22
Parent Publication: The Lancet. Infectious diseases
Issue: 5
ISSN: 1473-3099